LV12231B - DISPLAY MACROMOLECULAR COMPOSITION - Google Patents

DISPLAY MACROMOLECULAR COMPOSITION Download PDF

Info

Publication number: LV12231B
Authority: LV; Latvia
Prior art keywords: macromolecule; pārticies; drying; particles; gas
Prior art date: 1996-05-08

Application number

LVP-98-273A

Other languages

English (en)

Latvian (lv)

Other versions

LV12231A (lv

Inventor

Robert M. Platz

Thomas K. BREWER

Terence D. Boardman

Original Assignee

Inhale Therapeutic Systems, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-08

Filing date

1998-11-30

Publication date

1999-10-20

1998-11-30 Application filed by Inhale Therapeutic Systems, Inc. filed Critical Inhale Therapeutic Systems, Inc.

1999-03-20 Publication of LV12231A publication Critical patent/LV12231A/xx

1999-10-20 Publication of LV12231B publication Critical patent/LV12231B/en

Links

229920002521 macromolecule Polymers 0.000 title abstract description 67
239000000203 mixture Substances 0.000 title abstract description 57
238000000034 method Methods 0.000 title description 77
238000002360 preparation method Methods 0.000 title description 7
239000000843 powder Substances 0.000 abstract description 94
239000002245 particle Substances 0.000 abstract description 45
238000001035 drying Methods 0.000 abstract description 44
238000000889 atomisation Methods 0.000 abstract description 28
238000012384 transportation and delivery Methods 0.000 abstract description 27
230000002685 pulmonary effect Effects 0.000 abstract description 22
238000004519 manufacturing process Methods 0.000 abstract description 6
230000001225 therapeutic effect Effects 0.000 abstract description 5
239000006193 liquid solution Substances 0.000 abstract 1
239000007789 gas Substances 0.000 description 55
239000007788 liquid Substances 0.000 description 38
239000003814 drug Substances 0.000 description 29
229940079593 drug Drugs 0.000 description 27
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
239000000243 solution Substances 0.000 description 25
239000007921 spray Substances 0.000 description 19
238000001694 spray drying Methods 0.000 description 19
239000002609 medium Substances 0.000 description 18
210000004072 lung Anatomy 0.000 description 15
102000004877 Insulin Human genes 0.000 description 13
108090001061 Insulin Proteins 0.000 description 13
229940125396 insulin Drugs 0.000 description 13
238000000926 separation method Methods 0.000 description 13
230000008569 process Effects 0.000 description 12
239000006185 dispersion Substances 0.000 description 11
238000009826 distribution Methods 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000012530 fluid Substances 0.000 description 9
239000007787 solid Substances 0.000 description 9
239000000443 aerosol Substances 0.000 description 8
238000010981 drying operation Methods 0.000 description 8
239000000969 carrier Substances 0.000 description 7
239000000835 fiber Substances 0.000 description 7
150000004676 glycans Chemical class 0.000 description 7
239000000463 material Substances 0.000 description 7
238000004806 packaging method and process Methods 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
229920001282 polysaccharide Polymers 0.000 description 7
239000005017 polysaccharide Substances 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
230000000694 effects Effects 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
230000035515 penetration Effects 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
229930195725 Mannitol Natural products 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
239000000594 mannitol Substances 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000001509 sodium citrate Substances 0.000 description 5
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
201000003883 Cystic fibrosis Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
208000005176 Hepatitis C Diseases 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
102000003982 Parathyroid hormone Human genes 0.000 description 3
108090000445 Parathyroid hormone Proteins 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000012159 carrier gas Substances 0.000 description 3
230000004087 circulation Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000004744 fabric Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
208000002672 hepatitis B Diseases 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000199 parathyroid hormone Substances 0.000 description 3
229960001319 parathyroid hormone Drugs 0.000 description 3
230000002572 peristaltic effect Effects 0.000 description 3
238000005498 polishing Methods 0.000 description 3
229920001296 polysiloxane Polymers 0.000 description 3
238000012383 pulmonary drug delivery Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000010977 unit operation Methods 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010006458 Bronchitis chronic Diseases 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
102000003996 Interferon-beta Human genes 0.000 description 2
108090000467 Interferon-beta Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 2
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
208000020221 Short stature Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
101710142969 Somatoliberin Proteins 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
208000007451 chronic bronchitis Diseases 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000011888 foil Substances 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
230000005484 gravity Effects 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
229960001388 interferon-beta Drugs 0.000 description 2
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000002650 laminated plastic Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000035699 permeability Effects 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
239000002002 slurry Substances 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 1
PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000014429 Insulin-like growth factor Human genes 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
229920002884 Laureth 4 Polymers 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
230000018199 S phase Effects 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
108010078233 Thymalfasin Proteins 0.000 description 1
102400000800 Thymosin alpha-1 Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
206010060872 Transplant failure Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
238000012387 aerosolization Methods 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical class C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000012993 chemical processing Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
208000016532 chronic granulomatous disease Diseases 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000005056 compaction Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000000498 cooling water Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
239000003599 detergent Substances 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229940062711 laureth-9 Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
229960002259 nedocromil sodium Drugs 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000005457 optimization Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000004482 other powder Substances 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
208000027232 peripheral nervous system disease Diseases 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000001812 pycnometry Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
238000004513 sizing Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000010378 sodium ascorbate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
229960005055 sodium ascorbate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000005211 surface analysis Methods 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
229960004231 thymalfasin Drugs 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000000827 velocimetry Methods 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Zoology (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Glanulating (AREA)

LVP-98-273A 1996-05-08 1998-11-30 DISPLAY MACROMOLECULAR COMPOSITION LV12231B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/644,681 US6051256A (en)	1994-03-07	1996-05-08	Dispersible macromolecule compositions and methods for their preparation and use
PCT/US1997/007779 WO1997041833A1 (en)	1996-05-08	1997-05-07	Dispersible macromolecule compositions and methods for their preparation and use

Publications (2)

Publication Number	Publication Date
LV12231A LV12231A (lv)	1999-03-20
LV12231B true LV12231B (en)	1999-10-20

Family

ID=24585923

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-98-273A LV12231B (en)	1996-05-08	1998-11-30	DISPLAY MACROMOLECULAR COMPOSITION

Country Status (30)

Country	Link
US (5)	US6051256A (zh)
EP (1)	EP0948317A4 (zh)
JP (2)	JP2000510471A (zh)
CN (1)	CN1138531C (zh)
AP (1)	AP987A (zh)
AU (1)	AU730059B2 (zh)
BG (1)	BG64113B1 (zh)
BR (1)	BR9709057A (zh)
CA (1)	CA2253393C (zh)
CZ (1)	CZ295644B6 (zh)
EA (1)	EA000956B1 (zh)
EE (1)	EE03591B1 (zh)
GE (1)	GEP20012345B (zh)
HK (1)	HK1020319A1 (zh)
IL (1)	IL126754A (zh)
IS (1)	IS4879A (zh)
LT (1)	LT4553B (zh)
LV (1)	LV12231B (zh)
NO (1)	NO985196L (zh)
NZ (1)	NZ332480A (zh)
OA (1)	OA10914A (zh)
PL (1)	PL190732B1 (zh)
RO (1)	RO118523B1 (zh)
SI (1)	SI9720031A (zh)
SK (1)	SK285400B6 (zh)
TR (1)	TR199802247T2 (zh)
TW (1)	TW550089B (zh)
UA (1)	UA65538C2 (zh)
WO (1)	WO1997041833A1 (zh)
YU (1)	YU49206B (zh)

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
DE69332105T2 (de) *	1992-09-29	2003-03-06	Inhale Therapeutic Systems, San Carlos	Pulmonale abgabe von aktiven fragmenten des parathormons
US6024090A (en) *	1993-01-29	2000-02-15	Aradigm Corporation	Method of treating a diabetic patient by aerosolized administration of insulin lispro
US7448375B2 (en) *	1993-01-29	2008-11-11	Aradigm Corporation	Method of treating diabetes mellitus in a patient
US5830853A (en)	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US20010003739A1 (en) *	1993-06-24	2001-06-14	Astrazeneca Ab	Systemic administration of a therapeutic preparation
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
KR100419037B1 (ko) *	1994-03-07	2004-06-12	넥타르 테라퓨틱스	폐를통한인슐린의전달방법및그조성물
US6051256A (en) *	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
ATE299892T1 (de) *	1994-05-18	2005-08-15	Nektar Therapeutics	Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
EE9700136A (et) *	1994-12-22	1997-12-15	Astra Aktiebolag	Paratüroidhormooni PTH sisaldav ravimpreparaat inhaleerimiseks
CA2206782C (en)	1994-12-22	2007-04-03	Astra Aktiebolag	Aerosol drug formulations
US6309671B1 (en)	1995-04-14	2001-10-30	Inhale Therapeutic Systems	Stable glassy state powder formulations
US6258341B1 (en)	1995-04-14	2001-07-10	Inhale Therapeutic Systems, Inc.	Stable glassy state powder formulations
US6019968A (en) *	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
US6165463A (en)	1997-10-16	2000-12-26	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
US6428771B1 (en) *	1995-05-15	2002-08-06	Pharmaceutical Discovery Corporation	Method for drug delivery to the pulmonary system
GB9515182D0 (en)	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
CA2244767C (en)	1996-01-24	2005-11-22	Byk Gulden Lomberg Chemische Fabrik Gmbh	Process for the production of powdered pulmonary surfactant preparations
US6503480B1 (en) *	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en)	1996-05-24	2001-07-03	The Penn Research Foundation	Porous particles for deep lung delivery
US20030203036A1 (en) *	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20030035778A1 (en) *	1997-07-14	2003-02-20	Robert Platz	Methods and compositions for the dry powder formulation of interferon
GEP20022707B (en)	1997-07-18	2002-06-25	Infimed Inc Us	Biodegrading Macromers for the Controlled Release of Biologically Active Substances
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6309623B1 (en) *	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6946117B1 (en)	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US6433040B1 (en)	1997-09-29	2002-08-13	Inhale Therapeutic Systems, Inc.	Stabilized bioactive preparations and methods of use
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999055310A1 (en)	1998-04-27	1999-11-04	Altus Biologics Inc.	Stabilized protein crystals, formulations containing them and methods of making them
US6541606B2 (en)	1997-12-31	2003-04-01	Altus Biologics Inc.	Stabilized protein crystals formulations containing them and methods of making them
TW581681B (en)	1998-02-20	2004-04-01	Nektar Therapeutics	Liquid crystal forms of cyclosporin
WO1999055362A1 (en) *	1998-04-29	1999-11-04	Genentech, Inc.	Spray dried formulations of igf-i
US6284282B1 (en)	1998-04-29	2001-09-04	Genentech, Inc.	Method of spray freeze drying proteins for pharmaceutical administration
GB9810559D0 (en) *	1998-05-15	1998-07-15	Bradford Particle Design Ltd	Method and apparatus for particle formation
US6451349B1 (en) *	1998-08-19	2002-09-17	Quadrant Healthcare (Uk) Limited	Spray-drying process for the preparation of microparticles
US6956021B1 (en) *	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
US20070212422A1 (en) *	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
ES2261195T3 (es)	1999-04-05	2006-11-16	Mannkind Corporation	Metodo de formacion de particulas finas.
WO2000061178A1 (en) *	1999-04-13	2000-10-19	Inhale Therapeutics Systems, Inc.	Pulmonary administration of dry powder formulations for treating infertility
US7112341B1 (en)	1999-04-13	2006-09-26	Nektar Therapeutics	Pulmonary administration of dry powder formulations for treating infertility
ATE555773T1 (de)	1999-06-09	2012-05-15	Sievers Robert E	Überkritische fluidgestützte verneblung und blasen trochnen
US6858199B1 (en)	2000-06-09	2005-02-22	Advanced Inhalation Research, Inc.	High efficient delivery of a large therapeutic mass aerosol
EP2280020B1 (en) *	1999-06-29	2016-02-17	MannKind Corporation	Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
WO2001000312A1 (en) *	1999-06-30	2001-01-04	Inhale Therapeutic Systems, Inc.	Spray drying process for preparing dry powders
EP1074248A1 (en) *	1999-07-08	2001-02-07	Arnold Hilgers	Delivery system for biological material
ITMI991582A1 (it) *	1999-07-16	2001-01-16	Chiesi Farma Spa	Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
US6749835B1 (en)	1999-08-25	2004-06-15	Advanced Inhalation Research, Inc.	Formulation for spray-drying large porous particles
CA2382821A1 (en) *	1999-08-25	2001-03-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US20010036481A1 (en) *	1999-08-25	2001-11-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US6586008B1 (en) *	1999-08-25	2003-07-01	Advanced Inhalation Research, Inc.	Use of simple amino acids to form porous particles during spray drying
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
US7252840B1 (en)	1999-08-25	2007-08-07	Advanced Inhalation Research, Inc.	Use of simple amino acids to form porous particles
WO2001032144A1 (en)	1999-10-29	2001-05-10	Inhale Therapeutic Systems, Inc.	Dry powder compositions having improved dispersivity
US7507687B2 (en) *	2000-03-22	2009-03-24	Cabot Corporation	Electrocatalyst powders, methods for producing powder and devices fabricated from same
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA02001323A (es) *	2000-05-10	2004-07-16	Alliance Pharma	Microgranulos con base fosfolipida para la liberacion de farmaco.
US20030003057A1 (en) *	2000-07-07	2003-01-02	Jeffry Weers	Methods for administering leuprolide by inhalation
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7575761B2 (en) *	2000-06-30	2009-08-18	Novartis Pharma Ag	Spray drying process control of drying kinetics
WO2002009669A2 (en) *	2000-08-01	2002-02-07	Inhale Therapeutic Systems, Inc.	Apparatus and process to produce particles having a narrow size distribution and particles made thereby
WO2002011695A2 (en)	2000-08-07	2002-02-14	Inhale Therapeutic Systems, Inc.	Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP1328260A2 (en) *	2000-10-18	2003-07-23	Massachusetts Institute Of Technology	Methods and products related to pulmonary delivery of polysaccharides
DE60138641D1 (de)	2000-10-27	2009-06-18	Baxter Healthcare Sa	Herstellung von mikrokügelchen
GB0027357D0 (en)	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
US6896906B2 (en) *	2000-12-21	2005-05-24	Nektar Therapeutics	Storage stable powder compositions of interleukin-4 receptor
US20020141946A1 (en) *	2000-12-29	2002-10-03	Advanced Inhalation Research, Inc.	Particles for inhalation having rapid release properties
US6887462B2 (en)	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
US6848197B2 (en)	2001-04-18	2005-02-01	Advanced Inhalation Research, Inc.	Control of process humidity to produce large, porous particles
US20050282188A1 (en) *	2001-05-18	2005-12-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) *	2001-05-18	2005-09-15	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) *	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050233344A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) *	2001-11-30	2004-10-07	Mcswiggen James	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) *	2001-05-18	2006-10-26	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) *	2001-05-18	2005-06-02	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) *	2001-05-18	2005-10-13	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) *	2001-05-18	2005-08-18	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050287128A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) *	2001-05-18	2005-08-25	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) *	2001-05-18	2005-10-06	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050159376A1 (en) *	2002-02-20	2005-07-21	Slrna Therapeutics, Inc.	RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) *	2001-05-18	2008-07-03	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) *	2001-05-18	2007-02-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20070270579A1 (en) *	2001-05-18	2007-11-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) *	2001-05-18	2006-01-26	Sirna Therapeutics, Inc.	RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) *	2001-05-18	2005-06-30	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050014172A1 (en) *	2002-02-20	2005-01-20	Ivan Richards	RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) *	2001-05-18	2005-11-17	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050054596A1 (en) *	2001-11-30	2005-03-10	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) *	2001-05-18	2005-12-01	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20050148530A1 (en) *	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050159380A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) *	2001-05-18	2005-08-18	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
NZ519403A (en) *	2001-06-21	2005-03-24	Pfizer Prod Inc	Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
US20050123509A1 (en) *	2001-10-19	2005-06-09	Lehrman S. R.	Modulating charge density to produce improvements in the characteristics of spray-dried proteins
WO2003035051A2 (en) *	2001-10-19	2003-05-01	Inhale Therapeutic Systems, Inc.	The use of proton sequestering agents in drug formulations
EP1992335A1 (en) *	2001-11-01	2008-11-19	Nektar Therapeutics	Spray drying methods and compositions thereof
WO2003043585A2 (en) *	2001-11-20	2003-05-30	Advanced Inhalation Research, Inc.	Improved particulate compositions for pulmonary delivery
US20030099601A1 (en) *	2001-11-27	2003-05-29	Gordon Marc S.	Inhalation lung surfactant therapy
US20050075304A1 (en) *	2001-11-30	2005-04-07	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070203333A1 (en) *	2001-11-30	2007-08-30	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040138163A1 (en) *	2002-05-29	2004-07-15	Mcswiggen James	RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
SI1458360T1 (sl)	2001-12-19	2011-08-31	Novartis Ag	Pulmonalno dajanje aminoglikozidov
US20050042632A1 (en) *	2002-02-13	2005-02-24	Sirna Therapeutics, Inc.	Antibodies having specificity for nucleic acids
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050137153A1 (en) *	2002-02-20	2005-06-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
US20040014679A1 (en) *	2002-02-20	2004-01-22	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
CA2479212A1 (en) *	2002-03-15	2003-09-25	Brigham And Women's Hospital, Inc.	Central airway administration for systemic delivery of therapeutics
US20040063912A1 (en) *	2002-03-15	2004-04-01	The Brigham And Women's Hospital, Inc.	Central airway administration for systemic delivery of therapeutics
ES2300568T3 (es)	2002-03-20	2008-06-16	Mannkind Corporation	Aparato de inhalacion.
CA2478327A1 (en) *	2002-03-20	2003-10-02	Advanced Inhalation Research, Inc.	Hgh (human growth hormone) formulations for pulmonary administration
US20050163725A1 (en) *	2002-03-20	2005-07-28	Blizzard Charles D.	Method for administration of growth hormone via pulmonary delivery
US7008644B2 (en) *	2002-03-20	2006-03-07	Advanced Inhalation Research, Inc.	Method and apparatus for producing dry particles
CN101287449B (zh) *	2002-04-11	2010-11-03	米迪缪尼有限公司	喷雾干燥保存生物活性材料
GB0216562D0 (en) *	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US20040087543A1 (en) *	2002-04-25	2004-05-06	Zachary Shriver	Methods and products for mucosal delivery
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
DE10234165B4 (de) *	2002-07-26	2008-01-03	Advanced Micro Devices, Inc., Sunnyvale	Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
JP4680601B2 (ja) *	2002-12-17	2011-05-11	メディミューン・エルエルシー	生物活性材料の高圧噴霧乾燥
JP5591434B2 (ja)	2002-12-20	2014-09-17	ゼリスファーマシューティカルズインコーポレイテッド	皮内注射方法
AU2003302329B2 (en) *	2002-12-30	2010-01-07	Novartis Ag	Prefilming atomizer
WO2004060903A2 (en) *	2002-12-31	2004-07-22	Nektar Therapeutics	Aerosolizable pharmaceutical formulation for fungal infection therapy
CN1741789A (zh) *	2002-12-31	2006-03-01	尼克塔治疗公司	具有不溶解的活性物质的药物制剂
KR100500675B1 (ko) *	2003-02-10	2005-07-11	주식회사 에이앤피사이언스	고유량 입자 분무장치
GB0304540D0 (en) *	2003-02-27	2003-04-02	Elan Drug Delivery Ltd	Particle formulation and its preparation
KR20060015316A (ko) *	2003-05-28	2006-02-16	넥타르 테라퓨틱스	아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
US20050014230A1 (en) *	2003-07-16	2005-01-20	Ccl Holding Co., Ltd.	Preparation of fully human antibodies
DE04757306T1 (de) *	2003-07-28	2005-12-29	Pioneer Hi-Bred International, Inc.	Vorrichtung und verfahren zur aufbringung von substanzen an geerntete futterpflanzen und getreide
US20050042179A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
US20050043247A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
US20050042178A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US20050042180A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
GB0327723D0 (en) *	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
US7560444B2 (en) *	2003-10-01	2009-07-14	Momenta Pharmaceuticals, Inc.	Polysaccharides for pulmonary delivery of active agents
US7338171B2 (en) *	2003-10-27	2008-03-04	Jen-Chuen Hsieh	Method and apparatus for visual drive control
US20050214224A1 (en) *	2003-11-04	2005-09-29	Nektar Therapeutics	Lipid formulations for spontaneous drug encapsulation
KR20050056799A (ko) *	2003-12-10	2005-06-16	엘지.필립스 엘시디 주식회사	액정 표시패널의 실 패턴 구조
EP1701714A2 (en)	2004-01-07	2006-09-20	Nektar Therapeutics	Improved sustained release compositions for pulmonary administration of insulin
US20050153874A1 (en) *	2004-01-12	2005-07-14	Mannkind Corporation	Method of reducing serum proinsulin levels in type 2 diabetics
WO2005079755A2 (en) *	2004-02-12	2005-09-01	Nektar Therapeutics	Interleukin-13 antagonist powders, spray-dried particles, and methods
US20080090753A1 (en)	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
ES2328048T3 (es) *	2004-03-12	2009-11-06	Biodel, Inc.	Composiciones de insulina con absorcion mejorada.
KR20120089705A (ko) *	2004-04-23	2012-08-13	사이덱스 파마슈티칼스, 인크.	술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
DE102004022928A1 (de) *	2004-05-10	2005-12-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pulver enthaltend neuartige Oligosacharidgemische und Verfahren zu deren Herstellung
US7611709B2 (en)	2004-05-10	2009-11-03	Boehringer Ingelheim Pharma Gmbh And Co. Kg	1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en)	2004-05-10	2010-05-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
DE102004022926A1 (de) *	2004-05-10	2005-12-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Sprühgetrocknete Pulver enthaltend zumindest ein 1,4 O-verknüpftes Saccharose-Derivat und Verfahren zu deren Herstellung
US7727962B2 (en)	2004-05-10	2010-06-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Powder comprising new compositions of oligosaccharides and methods for their preparation
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US8513204B2 (en) *	2004-06-21	2013-08-20	Novartis Ag	Compositions comprising amphotericin B, mehods and systems
MXPA06015220A (es) *	2004-06-21	2007-12-13	Nektar Therapeutics	Composiciones comprendiendo anfotericina b, metodos y sistemas.
CN101027318B (zh)	2004-07-19	2016-05-25	比奥孔有限公司	胰岛素-低聚物共轭物，制剂及其用途
US20060024272A1 (en)	2004-07-29	2006-02-02	Large Scale Biology Corporation	C-terminally truncated interferon
BRPI0514263B8 (pt)	2004-08-20	2021-05-25	Mannkind Corp	método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
KR101306384B1 (ko)	2004-08-23	2013-09-09	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
SE0402345L (sv) *	2004-09-24	2006-03-25	Mederio Ag	Uppmätt läkemedelsdos
US9149433B2 (en) *	2004-11-30	2015-10-06	Basf Corporation	Method for formation of micro-prilled polymers
EP1819639A4 (en) *	2004-11-30	2012-05-02	Univ Tulane	DESTROYING TREATMENT PROCEDURE
WO2006076097A2 (en) *	2004-12-07	2006-07-20	Nektar Therapeutics	Stable non-crystalline formulation comprising losartan
US20080213593A1 (en) *	2005-01-21	2008-09-04	President And Fellows Of Harvard College	Systems And Methods For Forming Fluidic Droplets Encapsulated In Particles Such As Colloidal Particles
US20090053314A1 (en) *	2005-03-22	2009-02-26	Regeron, Inc.	Submicronization of proteins using supercritical fluids
WO2007030162A2 (en)	2005-05-18	2007-03-15	Nektar Therapeutics	Valves, devices, and methods for endobronchial therapy
WO2007019554A2 (en) *	2005-08-08	2007-02-15	Momenta Pharmaceuticals, Inc.	Polysaccharides for delivery of active agents
MX381952B (es)	2005-09-14	2025-03-13	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8084420B2 (en) *	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) *	2005-09-29	2007-04-12	Biodel, Inc.	Rapid acting and prolonged acting insulin preparations
US7713929B2 (en)	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
ES2390286T3 (es)	2005-12-16	2012-11-08	Nektar Therapeutics	Conjugados poliméricos de GLP-1
WO2007102946A2 (en)	2006-01-23	2007-09-13	Amgen Inc.	Crystalline polypeptides
KR102109867B1 (ko) *	2006-01-24	2020-05-13	안선 바이오파르마, 아이엔씨.	고분자 미소 구체들의 조제를 위한 기술
GB0602897D0 (en) *	2006-02-13	2006-03-22	Jagotec Ag	Improvements In Or Relating To Dry Powder Inhaler Devices
JP5599975B2 (ja)	2006-02-22	2014-10-01	マンカインドコーポレイション	ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
CA2649109A1 (en) *	2006-04-12	2007-10-25	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
EP2080408B1 (en)	2006-10-23	2012-08-15	Starkey Laboratories, Inc.	Entrainment avoidance with an auto regressive filter
GB0622818D0 (en) *	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
GB0625303D0 (en) *	2006-12-19	2007-01-24	Jagotec Ag	Improvements in and relating to metered dose inhalers
US7985058B2 (en) *	2007-01-12	2011-07-26	Mark Gray	Method and apparatus for making uniformly sized particles
WO2008124522A2 (en) *	2007-04-04	2008-10-16	Biodel, Inc.	Amylin formulations
EP2152304B1 (en)	2007-05-02	2018-08-22	The Regents of the University of Michigan	Nanoemulsion therapeutic compositions and methods of using the same
WO2009045553A1 (en)	2007-10-05	2009-04-09	Barofold, Inc.	High pressure treatment of aggregated interferons
WO2011163272A1 (en)	2010-06-21	2011-12-29	Mannkind Corporation	Dry powder drug delivery system and methods
WO2009082648A1 (en) *	2007-12-21	2009-07-02	Inspiration Biopharmaceuticals, Inc.	Stabilized factor ix formulations containing trehalose
EP2077132A1 (en)	2008-01-02	2009-07-08	Boehringer Ingelheim Pharma GmbH & Co. KG	Dispensing device, storage device and method for dispensing a formulation
AU2009204309B2 (en) *	2008-01-04	2012-11-22	Biodel, Inc.	Insulin formulations for insulin release as a function of tissue glucose levels
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
BRPI0913021A2 (pt) *	2008-05-15	2015-10-13	Novartis Ag	distribuição pulmonar de uma fluoroquinolona
KR101762089B1 (ko)	2008-06-13	2017-07-26	맨카인드 코포레이션	건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
EP2334234A4 (en)	2008-09-19	2013-03-20	Tandem Diabetes Care Inc	DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
CA2737040C (en)	2008-09-19	2017-05-02	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
EP2349209A2 (en) *	2008-09-26	2011-08-03	Nanobio Corporation	Nanoemulsion therapeutic compositions and methods of using the same
CN102239264B (zh)	2008-10-03	2013-11-20	纳幕尔杜邦公司	含羧酸酯制剂中过水解酶的稳定
WO2010057197A1 (en)	2008-11-17	2010-05-20	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
US9827205B2 (en) *	2008-12-12	2017-11-28	Mallinckrodt Pharma Ip Trading D.A.C.	Dry powder fibrin sealant
DK2379511T3 (en)	2008-12-29	2015-01-12	Mannkind Corp	Substituted diketopiperazinanaloger for use as pharmaceutical management funds
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
AU2010217760B2 (en)	2009-02-27	2015-04-09	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US9250106B2 (en)	2009-02-27	2016-02-02	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
US8538707B2 (en)	2009-03-11	2013-09-17	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
WO2010107964A1 (en)	2009-03-18	2010-09-23	Pleiades Cardio-Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2010107952A2 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120029054A1 (en)	2009-03-19	2012-02-02	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010107955A2 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
EP2408458A1 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521763A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
CN102439152A (zh)	2009-03-27	2012-05-02	默沙东公司	使用短干扰核酸（siNA）的RNA干扰介导的细胞间粘附分子1（ICAM-1）基因表达的抑制
JP2012521760A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111490A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010112358A2 (de)	2009-03-31	2010-10-07	Boehringer Ingelheim International Gmbh	Verfahren zur beschichtung einer oberfläche eines bauteils
EP2413903A4 (en)	2009-04-01	2013-01-02	Promedior Inc	PULMONARY AND NASAL ADMINISTRATION OF AMYLOID P SERUM SUBSTANCE
WO2010133294A2 (de)	2009-05-18	2010-11-25	Boehringer Ingelheim International Gmbh	Adapter, inhalationseinrichtung und zerstäuber
CA2764759A1 (en)	2009-06-09	2010-12-16	Defyrus, Inc.	Administration of interferon for prophylaxis against or treatment of pathogenic infection
MX2011013312A (es)	2009-06-12	2012-01-25	Mankind Corp	Microparticulas de dicetopiperazina con areas de superficie especificas definidas.
AU2010278894B2 (en)	2009-07-30	2014-01-30	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US8222012B2 (en)	2009-10-01	2012-07-17	E. I. Du Pont De Nemours And Company	Perhydrolase for enzymatic peracid production
PL2496246T3 (pl)	2009-11-03	2018-09-28	Grifols Therapeutics Llc	Kompozycja, sposób i zestaw dla inhibitora proteinazy alpha-1
EP2496295A1 (en)	2009-11-03	2012-09-12	MannKind Corporation	An apparatus and method for simulating inhalation efforts
JP5658268B2 (ja)	2009-11-25	2015-01-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ネブライザ
US10016568B2 (en)	2009-11-25	2018-07-10	Boehringer Ingelheim International Gmbh	Nebulizer
JP5715640B2 (ja)	2009-11-25	2015-05-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ネブライザ
EP2330094B1 (en) *	2009-12-03	2017-02-08	PURAC Biochem BV	Alkali metal cinnamate powder and method for preparation
PT2509991E (pt) *	2009-12-09	2016-01-12	Nitto Denko Corp	Modulação da expressão de hsp47
CN101816913B (zh) *	2010-05-20	2015-10-21	吴传斌	一种微球制造方法及制造设备
JP5874724B2 (ja)	2010-06-24	2016-03-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ネブライザ
US20120046225A1 (en)	2010-07-19	2012-02-23	The Regents Of The University Of Colorado, A Body Corporate	Stable glucagon formulations for the treatment of hypoglycemia
US8993522B2 (en)	2010-09-24	2015-03-31	University Of Florida Research Foundation, Inc.	Materials and methods for improving gastrointestinal function
US9260471B2 (en)	2010-10-29	2016-02-16	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
AU2012204462A1 (en)	2011-01-05	2013-07-11	Hospira, Inc.	Spray drying vancomycin
DK2673072T3 (en) *	2011-02-10	2015-02-16	Crucell Holland Bv	CELL SEPARATION SYSTEM WITH MEMBRANE WITH PNEUMATIC ALTERNATIVE PRESSURE
US9808030B2 (en)	2011-02-11	2017-11-07	Grain Processing Corporation	Salt composition
US8708159B2 (en) *	2011-02-16	2014-04-29	Oakwood Laboratories, Llc	Manufacture of microspheres using a hydrocyclone
EP2678059B1 (en)	2011-02-25	2021-04-07	Koninklijke Philips N.V.	An aerosol generating device for nebulizing a liquid
CN103492572A (zh)	2011-03-03	2014-01-01	夸克医药公司	用于治疗肺疾病和损伤的组合物和方法
EP3225235B1 (en)	2011-03-10	2020-12-16	Xeris Pharmaceuticals, Inc.	Stable peptide formulations for parenteral injection
JP6063877B2 (ja)	2011-03-10	2017-01-18	ゼリスファーマシューティカルズインコーポレイテッド	ペプチド薬物の非経口注射用の安定な製剤
ES2625858T3 (es)	2011-04-01	2017-07-20	Mannkind Corporation	Paquete de tipo blíster para cartuchos farmacéuticos
EP2694220B1 (de)	2011-04-01	2020-05-06	Boehringer Ingelheim International GmbH	Medizinisches gerät mit behälter
US9572774B2 (en)	2011-05-19	2017-02-21	Savara Inc.	Dry powder vancomycin compositions and associated methods
JP6012716B2 (ja) *	2011-05-19	2016-10-25	サヴァラ，インク．	乾燥粉末バンコマイシン組成物および関連する方法
US9827384B2 (en)	2011-05-23	2017-11-28	Boehringer Ingelheim International Gmbh	Nebulizer
US10196637B2 (en)	2011-06-08	2019-02-05	Nitto Denko Corporation	Retinoid-lipid drug carrier
US9011903B2 (en)	2011-06-08	2015-04-21	Nitto Denko Corporation	Cationic lipids for therapeutic agent delivery formulations
RU2769872C2 (ru)	2011-06-08	2022-04-07	Нитто Денко Корпорейшн	СОЕДИНЕНИЯ ДЛЯ НАЦЕЛЕННОЙ ДОСТАВКИ ЛЕКАРСТВЕННОГО СРЕДСТВА И УСИЛЕНИЯ АКТИВНОСТИ siPHK
TWI658830B (zh)	2011-06-08	2019-05-11	日東電工股份有限公司	Ｈｓｐ47表現調控強化用類視色素脂質體
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
CN103945859A (zh)	2011-10-24	2014-07-23	曼金德公司	用于治疗疼痛的方法和组合物
IN2014CN03555A (zh)	2011-10-25	2015-07-03	Onclave Therapeutics Ltd
EP2773331B1 (en)	2011-10-31	2016-02-10	Xeris Pharmaceuticals, Inc.	Formulations for the treatment of diabetes
WO2013067281A1 (en) *	2011-11-04	2013-05-10	Battelle Memorial Institute	Processes for producing protein microparticles
EP2601941A1 (en)	2011-12-06	2013-06-12	Ludwig-Maximilians-Universität München	Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
JP2015500712A (ja)	2011-12-16	2015-01-08	ノバルティスアーゲー	吸入プロファイルに依存しない薬剤送達のためのエアロゾル投与装置
WO2013114374A1 (en)	2012-02-01	2013-08-08	Protalix Ltd.	Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013151744A1 (en)	2012-04-05	2013-10-10	University Of Florida Research Foundation, Inc.	Materials and methods for treatment of cystic fibrosis and for induction of ion secretion
US8753643B1 (en)	2012-04-11	2014-06-17	Life-Science Innovations, Llc	Spray dried compositions and methods of use
WO2013152894A1 (de)	2012-04-13	2013-10-17	Boehringer Ingelheim International Gmbh	Zerstäuber mit kodiermitteln
BR112014025518B1 (pt)	2012-04-13	2022-05-24	Glaxosmithkline Intellectual Property Development Limited	Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9125805B2 (en)	2012-06-27	2015-09-08	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of small molecule drugs
WO2014005103A2 (en)	2012-06-28	2014-01-03	Ansun Biopharma, Inc.	Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
CN108057154B (zh)	2012-07-12	2021-04-16	曼金德公司	干粉药物输送系统和方法
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
US9757395B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9757529B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9018162B2 (en)	2013-02-06	2015-04-28	Xeris Pharmaceuticals, Inc.	Methods for rapidly treating severe hypoglycemia
US9956287B2 (en)	2013-02-06	2018-05-01	Perosphere Inc.	Stable glucagon formulations
CN105120856B (zh)	2013-03-11	2019-07-09	佛罗里达大学研究基金会有限公司	用于改善肺功能和用于预防和/或治疗辐射诱发的肺并发症的材料和方法
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
CN104043104B (zh)	2013-03-15	2018-07-10	浙江创新生物有限公司	含盐酸万古霉素的喷雾干粉及其工业化制备方法
WO2014144895A1 (en)	2013-03-15	2014-09-18	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
EP3607941A1 (en)	2013-04-30	2020-02-12	Otitopic Inc.	Dry powder formulations and methods of use
WO2014207213A1 (en)	2013-06-28	2014-12-31	Medizinische Universität Innsbruck	Novel inhibitors of protein kinase c epsilon signaling
EP3021834A1 (en)	2013-07-18	2016-05-25	MannKind Corporation	Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
ES2836977T3 (es)	2013-08-09	2021-06-28	Boehringer Ingelheim Int	Nebulizador
EP3030298B1 (en)	2013-08-09	2017-10-11	Boehringer Ingelheim International GmbH	Nebulizer
JP6701086B2 (ja)	2014-02-20	2020-05-27	オティトピックインコーポレイテッド	吸入用の乾燥粉末製剤
WO2015148905A1 (en)	2014-03-28	2015-10-01	Mannkind Corporation	Use of ultrarapid acting insulin
IL247927B (en)	2014-05-07	2022-09-01	Boehringer Ingelheim Int	Container, nebulizer and use
NZ724724A (en)	2014-05-07	2022-01-28	Boehringer Ingelheim Int	Container, indicator device, and nebulizer
EP3139984B1 (en)	2014-05-07	2021-04-28	Boehringer Ingelheim International GmbH	Nebulizer
EP2947460A1 (en)	2014-05-22	2015-11-25	Medizinische Universität Wien	Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
US10258573B2 (en)	2014-07-08	2019-04-16	Amphastar Pharmaceuticals, Inc.	Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions
WO2016022831A1 (en)	2014-08-06	2016-02-11	Xeris Pharmaceuticals, Inc.	Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US10575417B2 (en)	2014-09-08	2020-02-25	The Stanley Works Israel Ltd.	Jobsite communications center
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US20170304459A1 (en)	2014-10-10	2017-10-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhalation delivery of conjugated oligonucleotide
ES2924988T3 (es)	2014-10-10	2022-10-13	Univ Michigan Regents	Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
DK3212212T3 (da)	2014-10-31	2020-12-21	Univ Monash	Pulverformulering
CA2968831A1 (en)	2014-11-24	2016-06-02	Entrinsic Health Solutions, Llc	Amino acid compositions for the treatment of symptoms of disease
CN107406837A (zh)	2015-01-04	2017-11-28	波塔力克斯有限公司	修饰的dna酶及其用途
WO2016135139A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016170102A1 (en)	2015-04-22	2016-10-27	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
CN108578847A (zh) *	2015-05-16	2018-09-28	苏州汉方医药有限公司	由手动悬浮微颗粒发生器和黄芪或黄芪甲苷组成的药盒
WO2016196976A1 (en)	2015-06-04	2016-12-08	Xeris Pharmaceuticals, Inc.	Glucagon delivery apparatuses and related methods
US9649364B2 (en)	2015-09-25	2017-05-16	Xeris Pharmaceuticals, Inc.	Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016201248A1 (en)	2015-06-10	2016-12-15	Xeris Pharmaceuticals, Inc.	Use of low dose glucagon
US11590205B2 (en)	2015-09-25	2023-02-28	Xeris Pharmaceuticals, Inc.	Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN108368143B (zh)	2015-12-09	2022-02-01	维也纳医科大学	用于癌症疗法的单马来酰亚胺官能化的铂化合物
CN106968984B (zh) *	2015-12-11	2020-10-23	松下知识产权经营株式会社	涡轮机
US10322168B2 (en)	2016-01-07	2019-06-18	Amphastar Pharmaceuticals, Inc.	High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
JP2019508383A (ja)	2016-01-15	2019-03-28	ウニベルジテートハンブルグＵｎｉｖｅｒｓｉｔａｅｔＨａｍｂｕｒｇ	Ｏ−ラムノシル残基を有するフラボノイド型化合物
WO2017127641A1 (en)	2016-01-20	2017-07-27	Flurry Powders	Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US11833118B2 (en)	2016-01-20	2023-12-05	Flurry Powders, Llc	Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
IL260335B2 (en)	2016-02-01	2023-10-01	Incarda Therapeutics Inc	Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CA3013988A1 (en)	2016-02-15	2017-08-24	Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh	Taf1 inhibitors for the therapy of cancer
EP3280414B1 (en)	2016-04-15	2023-08-23	Oxford University Innovation Limited	Adenosine receptor modulators for the treatment of circadian rhythm disorders
US10704425B2 (en) *	2016-07-14	2020-07-07	General Electric Company	Assembly for a gas turbine engine
MX2019003821A (es)	2016-10-04	2019-12-18	Univ Florida	Composiciones de aminoacidos y usos de las mismas.
MX2019005443A (es)	2016-11-14	2019-11-21	Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh	Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
WO2018209107A1 (en)	2017-05-10	2018-11-15	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
BR112019024549A2 (pt)	2017-05-22	2020-06-09	Insmed Inc	compostos derivados de glicopeptídeo e usos dos mesmos
ES2982668T3 (es)	2017-06-02	2024-10-17	Xeris Pharmaceuticals Inc	Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación
WO2019016240A1 (en)	2017-07-19	2019-01-24	Leadiant Biosciences Ltd	ADENOSINE DEAMINASE FOR TREATING OR IMPROVING SCLERRODERMIS ASSOCIATED VASCULOPATHY
EP3720850A1 (en)	2017-12-05	2020-10-14	ETH Zurich	New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
EP3768378A4 (en)	2018-03-22	2021-11-17	InCarda Therapeutics, Inc.	NEW METHOD TO SLOW THE VENTRICULAR RATE
MX2020010552A (es)	2018-04-06	2020-12-11	Zilentin AG	Derivados de bumetanida para el tratamiento de la hiperhidrosis.
US20210163406A1 (en)	2018-04-06	2021-06-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
ES2949701T3 (es)	2018-07-26	2023-10-02	Cvie Therapeutics Ltd	Compuestos similares al 17beta-heterociclil-digitalis para el tratamiento de la insuficiencia cardíaca
US20230067929A1 (en)	2018-12-17	2023-03-02	Tolremo Therapeutics Ag	Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
BR112021021775A2 (pt)	2019-04-29	2022-01-04	Insmed Inc	Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas
RU193395U1 (ru) *	2019-06-17	2019-10-28	Евгений Викторович Крейдин	Генератор сухого солевого аэрозоля
US11007185B2 (en)	2019-08-01	2021-05-18	Incarda Therapeutics, Inc.	Antiarrhythmic formulation
CN114728934B (zh)	2019-10-02	2024-08-27	托雷莫治疗股份公司	杂环衍生物、药物组合物和它们治疗或改善癌症的用途
WO2021064141A1 (en)	2019-10-02	2021-04-08	Tolremo Therapeutics Ag	Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
ES2970792T3 (es)	2019-10-09	2024-05-30	Windtree Therapeutics Inc	Derivados de androstano con actividad como estimuladores puros o predominantemente puros de SERCA2A para el tratamiento de la insuficiencia cardíaca
WO2021074418A1 (en)	2019-10-16	2021-04-22	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
IL292153A (en)	2019-10-16	2022-06-01	Cemm Forschungszentrum Fur Molekulare Medizin Gmbh	Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
EP4138884A1 (en)	2020-04-20	2023-03-01	Sorrento Therapeutics, Inc.	Pulmonary administration of ace2 polypeptides
AU2021295432A1 (en)	2020-06-25	2023-02-23	Tolremo Therapeutics Ag	Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
BR112022026550A2 (pt)	2020-06-27	2023-01-17	Crescenta Biosciences	Composição de compostos que modulam o metabolismo celular e métodos de uso
EP3939578A1 (en)	2020-07-13	2022-01-19	Novaremed Ltd.	Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
EP3964497A1 (en)	2020-09-04	2022-03-09	Friedrich-Alexander-Universität Erlangen-Nürnberg	Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
US20230416707A1 (en)	2020-10-07	2023-12-28	Protalix Ltd.	Long-acting dnase
WO2022079290A2 (en)	2020-10-16	2022-04-21	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Cullin ring ubiquitin ligase compounds and uses thereof
IL307402A (en)	2021-04-07	2023-12-01	Tolremo Therapeutics Ag	The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer
US12138243B2 (en)	2021-12-31	2024-11-12	Crescenta Biosciences	Antiviral use of FABP4 modulating compounds
WO2023150747A1 (en)	2022-02-07	2023-08-10	Insmed Incorporated	Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023203174A1 (en)	2022-04-20	2023-10-26	Proxygen Gmbh	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2025040546A1 (en)	2023-08-18	2025-02-27	Proxygen Gmbh	Pyrazole compounds as cullin ring ubiquitin ligase compounds

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE421211A (zh)	1936-05-02
GB621785A (en)	1943-07-27	1949-04-20	Teco Sa	Apparatus for the pulverisation of liquids in the form of aerosols
US2598525A (en) *	1950-04-08	1952-05-27	E & J Mfg Co	Automatic positive pressure breathing machine
US3362405A (en) *	1964-04-06	1968-01-09	Hamilton O. Hazel	Method and apparatus for admixing gas with solid particles
US3674901A (en) *	1966-07-26	1972-07-04	Nat Patent Dev Corp	Surgical sutures
US3425600A (en) *	1966-08-11	1969-02-04	Abplanalp Robert H	Pressurized powder dispensing device
DE2121066C3 (de)	1971-04-29	1974-05-30	Knapsack Ag, 5033 Huerth-Knapsack	Zerstäubungsdüse für einen Zerstäubungstrockner
US4052255A (en)	1971-10-07	1977-10-04	J. M. Huber Corporation	Spray dryer discharge system
US3790079A (en)	1972-06-05	1974-02-05	Rnb Ass Inc	Method and apparatus for generating monodisperse aerosol
US3825188A (en)	1973-03-23	1974-07-23	Par Wey Mfg Co	Liquid spray head
US4069819A (en) *	1973-04-13	1978-01-24	Societa Farmaceutici S.P.A.	Inhalation device
GB1479283A (en) *	1973-07-23	1977-07-13	Bespak Industries Ltd	Inhaler for powdered medicament
FR2257351A1 (en)	1974-01-11	1975-08-08	Obert Jean Claude	Aerosol device for solid vaccines - feed and breaker screws deliver material sideways into blower chamber
IT1016489B (it) *	1974-03-18	1977-05-30	Isf Spa	Inalatore
SU628930A1 (ru)	1974-11-26	1978-10-25	Московский научно-исследовательский институт туберкулеза	Устройство дл введени порошкообразного лекарственного вещества
US3964483A (en) *	1975-01-13	1976-06-22	Syntex Puerto Rico, Inc.	Inhalation device
US4005711A (en) *	1975-01-13	1977-02-01	Syntex Puerto Rico, Inc.	Inhalation device
FR2299011A1 (fr) *	1975-01-29	1976-08-27	Obert Jean Claude	Generateur d'aerosols de part
US3991304A (en) *	1975-05-19	1976-11-09	Hillsman Dean	Respiratory biofeedback and performance evaluation system
US4153689A (en) *	1975-06-13	1979-05-08	Takeda Chemical Industries, Ltd.	Stable insulin preparation for nasal administration
US4035317A (en)	1975-06-30	1977-07-12	American Cyanamid Company	Rapidly dissolving, water-soluble polymers and spray drying method for their production
GB1527605A (en)	1975-08-20	1978-10-04	Takeda Chemical Industries Ltd	Insulin preparation for intranasal administration
US3994421A (en) *	1975-09-29	1976-11-30	American Cyanamid Company	Unitary therapeutic aerosol dispenser
JPS5254709A (en)	1975-10-31	1977-05-04	Lion Corp	Multi-stage spray drying method
DK150716C (da)	1976-12-01	1987-10-26	Niro Atomizer As	Fremgangsmaade ved behandling af et pulver- eller partikelformet produkt og apparat til brug ved udoevelse af fremgangsmaaden
FI54093C (fi)	1976-12-20	1978-10-10	Outokumpu Oy	Saett att framstaella pulverformigt selen fraon raoselen
US4211769A (en) *	1977-08-24	1980-07-08	Takeda Chemical Industries, Ltd.	Preparations for vaginal administration
NL7712041A (en)	1977-11-01	1979-05-03	Handelmaatschappij Voorheen Be	Suction equipment for powdery material - incorporates ejector type suction pump and cyclone type separator
JPS5829150B2 (ja)	1977-12-03	1983-06-21	ナカヤ産業株式会社	噴霧装置
US4268460A (en) *	1977-12-12	1981-05-19	Warner-Lambert Company	Nebulizer
EP0005585B1 (en) *	1978-05-03	1981-08-12	FISONS plc	Inhalation device
US4253468A (en) *	1978-08-14	1981-03-03	Steven Lehmbeck	Nebulizer attachment
US4503035B1 (en) *	1978-11-24	1996-03-19	Hoffmann La Roche	Protein purification process and product
SU1003926A1 (ru)	1979-01-24	1983-03-15	Всесоюзный Научно-Исследовательский И Конструкторский Институт Автогенного Машиностроения	Порошковый питатель
DE3013839A1 (de)	1979-04-13	1980-10-30	Freunt Ind Co Ltd	Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
IT1116047B (it) *	1979-04-27	1986-02-10	Sigma Tau Ind Farmaceuti	Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
JPS6034925B2 (ja) *	1979-07-31	1985-08-12	帝人株式会社	持続性鼻腔用製剤およびその製造法
NL8020393A (zh) *	1979-10-30	1981-09-01	Riker Laboratories, Inc. Te Loughborough, Groot-Brittannie.
US4294624A (en) *	1980-03-14	1981-10-13	Veltman Preston Leonard	Drying co-mingled carbohydrate solution and recycled product by dielectric heating
US4452239A (en) *	1980-03-25	1984-06-05	Hilal Malem	Medical nebulizing apparatus
US4484577A (en) *	1981-07-23	1984-11-27	Key Pharmaceuticals, Inc.	Drug delivery method and inhalation device therefor
US5260306A (en) *	1981-07-24	1993-11-09	Fisons Plc	Inhalation pharmaceuticals
DE3268533D1 (en) *	1981-07-24	1986-02-27	Fisons Plc	Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB2105189B (en)	1981-07-24	1985-03-20	Fisons Plc	Inhalation drugs
KR890000664B1 (ko)	1981-10-19	1989-03-22	바리 안소니 뉴우샘	미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
CH656077A5 (de)	1982-01-29	1986-06-13	Glatt Maschinen & Apparatebau	Verfahren zum ueberziehen von teilchen, insbesondere arzneimittel-teilchen, und vorrichtung zur durchfuehrung des verfahrens.
US4823784A (en) *	1982-04-30	1989-04-25	Cadema Medical Products, Inc.	Aerosol inhalation apparatus
US4659696A (en) *	1982-04-30	1987-04-21	Takeda Chemical Industries, Ltd.	Pharmaceutical composition and its nasal or vaginal use
IN160851B (zh) *	1982-10-08	1987-08-08	Glaxo Group Ltd
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
CA1200416A (en) *	1983-05-13	1986-02-11	Societe Des Produits Nestle S.A.	Food process
US4486435A (en)	1983-05-16	1984-12-04	Basf Wyandotte Corporation	Spray-dried vitamin powders using hydrophobic silica
US5038769A (en)	1983-06-29	1991-08-13	Krauser Robert S	Method and apparatus for treating ailments
US4649911A (en) *	1983-09-08	1987-03-17	Baylor College Of Medicine	Small particle aerosol generator for treatment of respiratory disease including the lungs
DE3345722A1 (de) *	1983-12-17	1985-06-27	Boehringer Ingelheim KG, 6507 Ingelheim	Inhalator
US4534343A (en) *	1984-01-27	1985-08-13	Trutek Research, Inc.	Metered dose inhaler
US4721709A (en)	1984-07-26	1988-01-26	Pyare Seth	Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4624251A (en) *	1984-09-13	1986-11-25	Riker Laboratories, Inc.	Apparatus for administering a nebulized substance
NZ209900A (en) *	1984-10-16	1989-08-29	Univ Auckland	Automatic inhaler
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
FR2575678B1 (fr) *	1985-01-04	1988-06-03	Saint Gobain Vitrage	Ejecteur pneumatique de poudre
US4942544A (en) *	1985-02-19	1990-07-17	Kenneth B. McIntosh	Medication clock
US4946828A (en) *	1985-03-12	1990-08-07	Novo Nordisk A/S	Novel insulin peptides
IL78342A (en) *	1985-04-04	1991-06-10	Gen Hospital Corp	Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
PT83094B (pt) *	1985-07-30	1993-07-30	Glaxo Group Ltd	Dispositivos proprios para a administracao de medicamentos a pacientes
US4702799A (en)	1985-09-03	1987-10-27	Nestec S.A.	Dryer and drying method
SE453566B (sv) *	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
US5017372A (en) *	1986-04-14	1991-05-21	Medicis Corporation	Method of producing antibody-fortified dry whey
US4739754A (en) *	1986-05-06	1988-04-26	Shaner William T	Suction resistant inhalator
US4926852B1 (en) *	1986-06-23	1995-05-23	Univ Johns Hopkins	Medication delivery system phase one
US4790305A (en) *	1986-06-23	1988-12-13	The Johns Hopkins University	Medication delivery system
US5042975A (en) *	1986-07-25	1991-08-27	Rutgers, The State University Of New Jersey	Iontotherapeutic device and process and iontotherapeutic unit dose
WO1988001165A1 (en) *	1986-08-11	1988-02-25	Innovata Biomed Limited	Pharmaceutical formulations comprising microcapsules
US4871489A (en)	1986-10-07	1989-10-03	Corning Incorporated	Spherical particles having narrow size distribution made by ultrasonic vibration
US4760093A (en)	1986-10-21	1988-07-26	American Home Products Corporation (Del.)	Spray dried acetaminophen
DE3636669C2 (de) *	1986-10-28	2001-08-16	Siemens Ag	Anordnung zur Zufuhr von Aerosol zu den Luftwegen und/oder Lungen eines Patienten
US5049388A (en) *	1986-11-06	1991-09-17	Research Development Foundation	Small particle aerosol liposome and liposome-drug combinations for medical use
US4833125A (en) *	1986-12-05	1989-05-23	The General Hospital Corporation	Method of increasing bone mass
DE3642106A1 (de)	1986-12-10	1988-06-16	Bayer Ag	Verfahren zur herstellung von polymerisatpulvern durch zerstaeubungstrocknung
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5114917A (en) *	1986-12-24	1992-05-19	John Lezdey	Treatment of inflammation using alpha 1-antichymotrypsin
US4784878A (en)	1987-04-06	1988-11-15	Damrow Company, Inc.	Spray drying method and apparatus for concurrent particle coating
GB8710290D0 (en)	1987-04-30	1987-06-03	Unilever Plc	Preparation of granular detergent composition
GB8712176D0 (en)	1987-05-22	1987-06-24	Cosmas Damian Ltd	Drug delivery system
US4835187A (en)	1987-06-15	1989-05-30	American Home Products Corporation	Spray dried ibuprofen
US5139016A (en) *	1987-08-07	1992-08-18	Sorin Biomedica S.P.A.	Process and device for aerosol generation for pulmonary ventilation scintigraphy
IT1222509B (it) *	1987-08-17	1990-09-05	Miat Spa	Insufflatore per la somministrazione di farmaci sotto forma di polvere predosata in opercoli
CH672048A5 (zh)	1987-09-16	1989-10-31	Nestle Sa
GB8723846D0 (en) *	1987-10-10	1987-11-11	Danbiosyst Ltd	Bioadhesive microsphere drug delivery system
US5081228A (en) *	1988-02-25	1992-01-14	Immunex Corporation	Interleukin-1 receptors
WO1989004838A1 (en) *	1987-11-25	1989-06-01	Immunex Corporation	Interleukin-1 receptors
US4968607A (en) *	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
JP2524379B2 (ja)	1988-01-29	1996-08-14	大川原化工機株式会社	ノズル装置とそれを組込んでなるスプレ―ドライヤ―装置
ES2047547T3 (es)	1988-06-03	1994-03-01	Niro Sterner Inc	Metodo de deshidratacion por aspersion y aparato para revestimiento simultaneo de particulas.
IT1217890B (it) *	1988-06-22	1990-03-30	Chiesi Farma Spa	Dispositivo per l'inalazione di aerosol dosati
US5066522A (en)	1988-07-14	1991-11-19	Union Carbide Chemicals And Plastics Technology Corporation	Supercritical fluids as diluents in liquid spray applications of adhesives
EP0360340A1 (en) *	1988-09-19	1990-03-28	Akzo N.V.	Composition for nasal administration containing a peptide
ES2051371T3 (es) *	1988-10-04	1994-06-16	Univ Johns Hopkins	Inhalador de aerosoles.
US4984158A (en) *	1988-10-14	1991-01-08	Hillsman Dean	Metered dose inhaler biofeedback training and evaluation system
DK479189D0 (da)	1989-01-06	1989-09-28	Hans Gernot Schenk	Inhalator
US5011678A (en) *	1989-02-01	1991-04-30	California Biotechnology Inc.	Composition and method for administration of pharmaceutically active substances
GB8903593D0 (en) *	1989-02-16	1989-04-05	Pafra Ltd	Storage of materials
IT1228459B (it) *	1989-02-23	1991-06-19	Phidea S R L	Inalatore con svuotamento regolare e completo della capsula.
GB8904370D0 (en)	1989-02-25	1989-04-12	Cosmas Damian Ltd	Liquid delivery compositions
SE466684B (sv) *	1989-03-07	1992-03-23	Draco Ab	Anordning vid en inhalator samt foerfarande foer att med anordningen registrera medicinering med inhalator
US5009367A (en)	1989-03-22	1991-04-23	Union Carbide Chemicals And Plastics Technology Corporation	Methods and apparatus for obtaining wider sprays when spraying liquids by airless techniques
US5206306A (en)	1989-03-31	1993-04-27	The B. F. Goodrich Company	Process for making a polymer for an optical substrate by hydrogenating a cycloolefin copolymer
FI84698C (fi)	1989-06-16	1992-01-10	Huhtamaeki Oy	Anordning foer finfoerdelning av agglomerat av en enkeldos av ett laekemedelpreparat i pulverform.
IT1230313B (it) *	1989-07-07	1991-10-18	Somova Spa	Inalatore per medicamenti in capsule.
US5232707A (en)	1989-07-10	1993-08-03	Syntex (U.S.A.) Inc.	Solvent extraction process
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
GB8918879D0 (en)	1989-08-18	1989-09-27	Danbiosyst Uk	Pharmaceutical compositions
US5238920A (en) *	1989-08-22	1993-08-24	Abbott Laboratories	Pulmonary surfactant protein fragments
IT1237118B (it) *	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
US5707644A (en) *	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
GB9001635D0 (en) *	1990-01-24	1990-03-21	Ganderton David	Aerosol carriers
US5113855A (en) *	1990-02-14	1992-05-19	Newhouse Michael T	Powder inhaler
DE4004904A1 (de) *	1990-02-16	1990-09-13	Gerhard Brendel	Trommel-applikator
WO1991016882A1 (en) *	1990-05-08	1991-11-14	Liposome Technology, Inc.	Direct spray-dried drug/lipid powder composition
US5000888A (en)	1990-05-23	1991-03-19	Basf Corporation	Process for spray drying riboflavin to produce a granulate product having low binder content
JP3282731B2 (ja)	1990-06-15	2002-05-20	メルクエンドカムパニーインコーポレーテッド	結晶の構造および大きさを改良する結晶化方法
IT1243344B (it) *	1990-07-16	1994-06-10	Promo Pack Sa	Inalatore plurimonodose per medicamenti in polvere
US5037912A (en) *	1990-07-26	1991-08-06	The Goodyear Tire & Rubber Company	Polymerization of 1,3-butadiene to trans-1,4-polybutadiene with organolithium and alkali metal alkoxide
GB9017155D0 (en)	1990-08-03	1990-09-19	Ici Plc	Spray drying
US5235969A (en) *	1990-08-20	1993-08-17	Intersurgical (Guernsey) Limited	Nebulizer having combined structure for removing particles over two microns
US5230884A (en) *	1990-09-11	1993-07-27	University Of Wales College Of Cardiff	Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5200399A (en) *	1990-09-14	1993-04-06	Boyce Thompson Institute For Plant Research, Inc.	Method of protecting biological materials from destructive reactions in the dry state
US5217004A (en) *	1990-12-13	1993-06-08	Tenax Corporation	Inhalation actuated dispensing apparatus
US5487378A (en) *	1990-12-17	1996-01-30	Minnesota Mining And Manufacturing Company	Inhaler
US5099833A (en) *	1991-02-19	1992-03-31	Baxter International Inc.	High efficiency nebulizer having a flexible reservoir
AU1442592A (en) *	1991-02-20	1992-09-15	Nova Pharmaceutical Corporation	Controlled release microparticulate delivery system for proteins
US5186164A (en) *	1991-03-15	1993-02-16	Puthalath Raghuprasad	Mist inhaler
DE59107894D1 (de) *	1991-03-21	1996-07-11	Ritzau Pari Werk Gmbh Paul	Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
GB9106648D0 (en) *	1991-03-28	1991-05-15	Rhone Poulenc Rorer Ltd	New inhaler
US5993805A (en)	1991-04-10	1999-11-30	Quadrant Healthcare (Uk) Limited	Spray-dried microparticles and their use as therapeutic vehicles
GB9107628D0 (en)	1991-04-10	1991-05-29	Moonbrook Limited	Preparation of diagnostic agents
DK0533683T3 (da) *	1991-04-15	1997-01-13	Leiras Oy	Indretning til måling af en dosis pulveriseret medikament til inhalering
DE4117751A1 (de)	1991-05-30	1992-12-03	Bayer Ag	Verfahren zur isolierung von polycarbonaten
AU662919B2 (en) *	1991-07-02	1995-09-21	Inhale, Inc.	Method and device for delivering aerosolized medicaments
GB9116610D0 (en)	1991-08-01	1991-09-18	Danbiosyst Uk	Preparation of microparticles
US5161524A (en) *	1991-08-02	1992-11-10	Glaxo Inc.	Dosage inhalator with air flow velocity regulating means
US5269980A (en)	1991-08-05	1993-12-14	Northeastern University	Production of polymer particles in powder form using an atomization technique
US6123924A (en)	1991-09-25	2000-09-26	Fisons Plc	Pressurized aerosol inhalation compositions
KR100259989B1 (ko)	1991-10-01	2000-08-01	모리다 가쓰라	서방성 마이크로캡슐 제제 및 그의 제조법
US5733731A (en)	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
GB9123953D0 (en)	1991-11-12	1992-01-02	Minnesota Mining & Mfg	Inhalation device
US5206219A (en) *	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
US5320094A (en) *	1992-01-10	1994-06-14	The Johns Hopkins University	Method of administering insulin
JPH07503154A (ja) *	1992-01-21	1995-04-06	エス・アール・アイ・インターナシヨナル	微細化ポリペプチド薬剤の改良調製方法
US5639441A (en)	1992-03-06	1997-06-17	Board Of Regents Of University Of Colorado	Methods for fine particle formation
CA2115065C (en)	1992-06-12	2000-10-03	Kiyoyuki Sakon	Ultrafine particle powder for inhalation and method for production thereof
US5376359A (en) *	1992-07-07	1994-12-27	Glaxo, Inc.	Method of stabilizing aerosol formulations
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
AU4198793A (en)	1992-07-24	1994-01-27	Takeda Chemical Industries Ltd.	Microparticle preparation and production thereof
DE69332105T2 (de)	1992-09-29	2003-03-06	Inhale Therapeutic Systems, San Carlos	Pulmonale abgabe von aktiven fragmenten des parathormons
GB9221329D0 (en)	1992-10-10	1992-11-25	Delta Biotechnology Ltd	Preparation of further diagnostic agents
RO113214B1 (ro)	1992-10-19	1998-05-29	Dura Pharma Inc	Inhalator de pulbere uscata
DE59309257D1 (de)	1992-10-26	1999-02-11	Sanol Arznei Schwarz Gmbh	Verfahren zur herstellung von mikrokapseln
GB9226474D0 (en)	1992-12-18	1993-02-10	Ici Plc	Production of particulate materials
US5364838A (en) *	1993-01-29	1994-11-15	Miris Medical Corporation	Method of administration of insulin
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
IL105658A (en)	1993-05-11	1995-10-31	Ultrasonic Dryer Ltd	Spray drying system
TW402506B (en) *	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US5506203C1 (en) *	1993-06-24	2001-02-06	Astra Ab	Systemic administration of a therapeutic preparation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5595761A (en)	1994-01-27	1997-01-21	The Board Of Regents Of The University Of Oklahoma	Particulate support matrix for making a rapidly dissolving tablet
US5635210A (en)	1994-02-03	1997-06-03	The Board Of Regents Of The University Of Oklahoma	Method of making a rapidly dissolving tablet
WO1995023613A1 (en)	1994-03-04	1995-09-08	Genentech, Inc.	PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
US6051256A (en) *	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
KR100419037B1 (ko) *	1994-03-07	2004-06-12	넥타르 테라퓨틱스	폐를통한인슐린의전달방법및그조성물
ATE299892T1 (de) *	1994-05-18	2005-08-15	Nektar Therapeutics	Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US5580856A (en) *	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
CA2199954A1 (en) *	1994-09-29	1996-04-04	Andrew Derek Sutton	Spray-dried microparticles as therapeutic vehicles
US6117455A (en)	1994-09-30	2000-09-12	Takeda Chemical Industries, Ltd.	Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
GB9423419D0 (en)	1994-11-19	1995-01-11	Andaris Ltd	Preparation of hollow microcapsules
US5970974A (en)	1995-03-14	1999-10-26	Siemens Aktiengesellschaft	Dosating unit for an ultrasonic atomizer device
US5922253A (en)	1995-05-18	1999-07-13	Alkermes Controlled Therapeutics, Inc.	Production scale method of forming microparticles
US5667806A (en) *	1995-06-07	1997-09-16	Emisphere Technologies, Inc.	Spray drying method and apparatus
US5607697A (en)	1995-06-07	1997-03-04	Cima Labs, Incorporated	Taste masking microparticles for oral dosage forms
GB9515182D0 (en)	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
US5687905A (en)	1995-09-05	1997-11-18	Tsai; Shirley Cheng	Ultrasound-modulated two-fluid atomization
DE19536902A1 (de)	1995-10-04	1997-04-10	Boehringer Ingelheim Int	Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
GB9607035D0 (en)	1996-04-03	1996-06-05	Andaris Ltd	Spray-dried microparticles as therapeutic vehicles
DE19617487A1 (de)	1996-05-02	1997-11-06	Merck Patent Gmbh	Geschmacksverbesserung von Arzneimittelwirkstoffen
US5985309A (en)	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US6503480B1 (en)	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5855913A (en)	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
TW305239U (en)	1996-06-28	1997-05-11	Ind Tech Res Inst	Generating apparatus of gaseous glue capable of distributing particles with narrow diameters
JP3585654B2 (ja)	1996-07-11	2004-11-04	株式会社パウダリングジャパン	２段乾燥式スプレードライヤー装置
US6017310A (en)	1996-09-07	2000-01-25	Andaris Limited	Use of hollow microcapsules
US20030203036A1 (en)	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US5985248A (en)	1996-12-31	1999-11-16	Inhale Therapeutic Systems	Processes for spray drying solutions of hydrophobic drugs and compositions thereof
US6383810B2 (en)	1997-02-14	2002-05-07	Invitrogen Corporation	Dry powder cells and cell culture reagents and methods of production thereof
US6051257A (en) *	1997-02-24	2000-04-18	Superior Micropowders, Llc	Powder batch of pharmaceutically-active particles and methods for making same
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
GB9727102D0 (en)	1997-12-22	1998-02-25	Andaris Ltd	Microparticles and their therapeutic use
GB9825883D0 (en)	1998-11-27	1999-01-20	Aea Technology Plc	Formation of monodisperse particles
US6223455B1 (en)	1999-05-03	2001-05-01	Acusphere, Inc.	Spray drying apparatus and methods of use
US20020081266A1 (en)	1999-08-20	2002-06-27	Norton Healthcare Ltd.	Spray dried powders for pulmonary or nasal administration
NL1013893C2 (nl)	1999-12-20	2001-06-21	Stork Friesland Bv	Inrichting voor het verstuiven van een vloeibaar product, een daarvan voorziene sproeidroog- en conditionerings-inrichting alsmede een werkwijze voor het conditioneren van een vloeibaar product.
US6656492B2 (en)	2000-06-30	2003-12-02	Yamanouchi Pharmaceutical Co., Ltd.	Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US6455028B1 (en)	2001-04-23	2002-09-24	Pharmascience	Ipratropium formulation for pulmonary inhalation
EP1992335A1 (en)	2001-11-01	2008-11-19	Nektar Therapeutics	Spray drying methods and compositions thereof

1996
- 1996-05-08 US US08/644,681 patent/US6051256A/en not_active Expired - Lifetime
1997
- 1997-05-07 EP EP97926420A patent/EP0948317A4/en not_active Withdrawn
- 1997-05-07 PL PL97329870A patent/PL190732B1/pl not_active IP Right Cessation
- 1997-05-07 AU AU31190/97A patent/AU730059B2/en not_active Ceased
- 1997-05-07 CN CNB971944709A patent/CN1138531C/zh not_active Expired - Fee Related
- 1997-05-07 EA EA199800983A patent/EA000956B1/ru not_active IP Right Cessation
- 1997-05-07 JP JP09540191A patent/JP2000510471A/ja not_active Withdrawn
- 1997-05-07 CZ CZ19983599A patent/CZ295644B6/cs not_active IP Right Cessation
- 1997-05-07 TR TR1998/02247T patent/TR199802247T2/xx unknown
- 1997-05-07 RO RO98-01547A patent/RO118523B1/ro unknown
- 1997-05-07 NZ NZ332480A patent/NZ332480A/xx unknown
- 1997-05-07 GE GEAP19974599A patent/GEP20012345B/en unknown
- 1997-05-07 EE EE9800376A patent/EE03591B1/xx not_active IP Right Cessation
- 1997-05-07 BR BR9709057A patent/BR9709057A/pt not_active Application Discontinuation
- 1997-05-07 WO PCT/US1997/007779 patent/WO1997041833A1/en active Application Filing
- 1997-05-07 SK SK1525-98A patent/SK285400B6/sk not_active IP Right Cessation
- 1997-05-07 YU YU50198A patent/YU49206B/sh unknown
- 1997-05-07 AP APAP/P/1998/001369A patent/AP987A/en active
- 1997-05-07 SI SI9720031A patent/SI9720031A/sl not_active IP Right Cessation
- 1997-05-07 IL IL12675497A patent/IL126754A/xx not_active IP Right Cessation
- 1997-05-07 CA CA002253393A patent/CA2253393C/en not_active Expired - Fee Related
- 1997-06-14 TW TW086108261A patent/TW550089B/zh not_active IP Right Cessation
- 1997-07-05 UA UA98126441A patent/UA65538C2/uk unknown
1998
- 1998-10-26 IS IS4879A patent/IS4879A/is unknown
- 1998-10-28 BG BG102875A patent/BG64113B1/bg unknown
- 1998-11-05 OA OA9800212A patent/OA10914A/en unknown
- 1998-11-06 NO NO985196A patent/NO985196L/no not_active Application Discontinuation
- 1998-11-09 LT LT98-157A patent/LT4553B/lt not_active IP Right Cessation
- 1998-11-30 LV LVP-98-273A patent/LV12231B/en unknown
1999
- 1999-11-29 HK HK99105537A patent/HK1020319A1/xx not_active IP Right Cessation
2000
- 2000-02-04 US US09/498,397 patent/US6423344B1/en not_active Expired - Lifetime
2001
- 2001-11-09 US US10/007,868 patent/US6592904B2/en not_active Expired - Fee Related
2003
- 2003-03-31 US US10/403,482 patent/US7138141B2/en not_active Expired - Fee Related
2006
- 2006-09-28 US US11/536,348 patent/US8173168B2/en not_active Expired - Fee Related
2009
- 2009-04-15 JP JP2009099209A patent/JP2009191071A/ja active Pending

Also Published As

Publication number	Publication date
IL126754A (en)	2003-06-24
SK285400B6 (sk)	2007-01-04
EA199800983A1 (ru)	1999-04-29
IS4879A (is)	1998-10-26
LT98157A (en)	1999-05-25
US6592904B2 (en)	2003-07-15
EE9800376A (et)	1999-04-15
JP2009191071A (ja)	2009-08-27
NZ332480A (en)	2000-01-28
TW550089B (en)	2003-09-01
US6423344B1 (en)	2002-07-23
CA2253393A1 (en)	1997-11-13
HK1020319A1 (en)	2000-04-14
SK152598A3 (en)	1999-04-13
CA2253393C (en)	2007-10-09
US7138141B2 (en)	2006-11-21
CN1138531C (zh)	2004-02-18
OA10914A (en)	2001-10-26
NO985196L (no)	1999-01-06
AU730059B2 (en)	2001-02-22
IL126754A0 (en)	1999-08-17
JP2000510471A (ja)	2000-08-15
US20030215514A1 (en)	2003-11-20
PL329870A1 (en)	1999-04-12
US20020122827A1 (en)	2002-09-05
EE03591B1 (et)	2002-02-15
GEP20012345B (en)	2001-01-25
LT4553B (lt)	1999-10-25
EP0948317A4 (en)	2006-02-01
LV12231A (lv)	1999-03-20
TR199802247T2 (xx)	2001-11-21
WO1997041833A1 (en)	1997-11-13
SI9720031A (sl)	1999-02-28
AP987A (en)	2001-08-01
EA000956B1 (ru)	2000-08-28
BR9709057A (pt)	1999-08-03
CN1218394A (zh)	1999-06-02
BG102875A (en)	1999-05-31
YU50198A (sh)	2000-12-28
US8173168B2 (en)	2012-05-08
AU3119097A (en)	1997-11-26
US20070020199A1 (en)	2007-01-25
AP9801369A0 (en)	1998-12-31
CZ295644B6 (cs)	2005-09-14
NO985196D0 (no)	1998-11-06
YU49206B (sh)	2004-09-03
US6051256A (en)	2000-04-18
EP0948317A1 (en)	1999-10-13
BG64113B1 (bg)	2004-01-30
UA65538C2 (en)	2004-04-15
CZ359998A3 (cs)	1999-03-17
PL190732B1 (pl)	2005-12-30
RO118523B1 (ro)	2003-06-30

Publication	Publication Date	Title
CA2253393C (en)	2007-10-09	Dispersible macromolecule compositions and methods for their preparation and use
WO1997041833A9 (en)	1998-02-12	Dispersible macromolecule compositions and methods for their preparation and use
US6509006B1 (en)	2003-01-21	Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US7097827B2 (en)	2006-08-29	Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments
US20030086877A1 (en)	2003-05-08	Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments
KR100473212B1 (ko)	2005-07-21	분산성고분자조성물과이의제조방법및용도
MXPA98009272A (en)	1999-10-14	Compositions of dispersible macromolecules and methods for their preparation and